Key Lung Journal Articles - Metastatic
Published: Fri Apr 29, 2011 Updated:Fri Dec 9, 2011
-
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
T Ciuleanu et al; January 24th, 2012; doi:10.1016/S1470-2045(11)70385-0
-
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
VA Miller et al; March 26th, 2012; doi:10.1016/S1470-2045(12)70087-6
-
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT):
L Paz-Ares et al; March 2012; doi:10.1016/S1470-2045(12)70063-3
-
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.
GV Scagliotti, et al; November 28, 2011; doi: 10.1200/JCO.2010.33.7089
-
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
R Pirker, The Lancet Oncology, Volume 13, Issue 1, Pages 33 - 42, January 2012
-
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw et al, Oct 2011; doi:10.1016/S1470-2045(11)70232-7
-
A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Bayer Study Director, 2007-2011
-
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
E Quoix et al, The Lancet. Sept 17 2011; 378(9796):1079 - 1088
-
Concurrent chemo and radiation therapy improves long-term survival for inoperable stage III lung cancer
WJ Curran Jr et al, RTOG
-
Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
WJ Curran Jr et al, Sep 8, 2011; doi: 10.1093/jnci/djr325
-
Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2
R Lilenbaum et al, JCO. Feb 20 2008; 26(6):863-869
-
Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
SS Ramalingam et al, JCO. Jan 1 2008; 26(1):60-65
-
Phase II Clinical Trial of Chemotherapy-Naïve Patients 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer
DM Jackman et al, JCO. Mar 1 2007; 25(7):760-6
-
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
LV Sequist et al, JCO. Feb 10 2007; 25(5):587-95
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
RE Rosell, et al; January 26, 2012; Doi : 10.1016/S1470-2045(11)70393-X
